Fintel reports that on November 4, 2024, Argus Research upgraded their outlook for AbbVie (NYSE:ABBV) from Hold to Buy.

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell resistance to current immunotherapies, has signed a collaboration and ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.